Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Prescient Therapeutics Limited ( (AU:PTX) ) has provided an announcement.
Prescient Therapeutics has announced an extension of its Share Purchase Plan (SPP) to raise up to $7 million, now closing on July 22, 2025. The funds will support the Phase 2 clinical development of PTX-100, a potential cancer treatment, reflecting the company’s commitment to advancing its pipeline and responding to shareholder feedback for more participation time.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is an ASX-listed biotechnology company focused on developing targeted and personalized cancer treatments. The company is engaged in advancing its innovative therapies through clinical development, aiming to provide effective solutions in the oncology sector.
Average Trading Volume: 971,908
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$33.82M
See more insights into PTX stock on TipRanks’ Stock Analysis page.